#1 Clinical Trials Search in Europe

Niflumic Acid

This article discusses a clinical trial investigating the use of Niflumic Acid, a non-steroidal anti-inflammatory drug (NSAID), as part of a walking rehabilitation program for patients with hip or knee osteoarthritis. The study aims to evaluate the effectiveness and tolerance of this treatment approach in improving patients’ mobility and quality of life.

Table of Contents

What is Niflumic Acid?

Niflumic Acid is a medication that belongs to a class of drugs called non-steroidal anti-inflammatory drugs (NSAIDs). It is primarily used to treat pain and inflammation associated with various conditions, including osteoarthritis[1]. In France, it is marketed under the brand name NIFLURIL 250 mg, in the form of a capsule (gélule in French).

Medical Uses

Niflumic Acid is primarily used in the treatment of:

  • Osteoarthritis: A degenerative joint disease that causes pain and stiffness in joints, particularly in the hip and knee[1].
  • Other inflammatory conditions: While not specifically mentioned in the provided clinical trial data, NSAIDs like Niflumic Acid are often used to treat various inflammatory conditions.

Dosage and Administration

According to the information provided:

  • The maximum daily dose of Niflumic Acid is 500 mg[1].
  • The maximum total dose over the course of treatment is 300 g[1].
  • The medication is taken orally, typically in capsule form[1].
  • The maximum treatment period mentioned is 12 weeks[1].

It’s important to note that these are maximum doses and treatment durations. Your doctor will prescribe the appropriate dosage for your specific condition and circumstances.

Potential Benefits

While the clinical trial data doesn’t provide specific information about the benefits of Niflumic Acid, NSAIDs like this medication are generally used to:

  • Reduce pain associated with osteoarthritis
  • Decrease inflammation in affected joints
  • Improve mobility and quality of life for patients with osteoarthritis

Precautions and Contraindications

Based on the information provided in the clinical trial data, there are several precautions and contraindications to consider when using NSAIDs like Niflumic Acid. While these are not specific to Niflumic Acid, they apply to the class of drugs it belongs to:

  • Allergic reactions: Patients with a history of hypersensitivity reactions to NSAIDs or aspirin should avoid this medication[1].
  • Gastrointestinal issues: Those with a history of gastrointestinal bleeding, perforation, or active peptic ulcers should use caution[1].
  • Liver and kidney function: Patients with severe liver or kidney problems may not be suitable candidates for this medication[1].
  • Cardiovascular health: People with uncontrolled high blood pressure or congestive heart failure should consult their doctor before using this medication[1].
  • Pregnancy and breastfeeding: Pregnant or breastfeeding women should avoid this medication[1].

Ongoing Research

A clinical trial named PERIPATEI is currently studying the use of NSAIDs, including Niflumic Acid, as part of a walking rehabilitation program for patients with hip or knee osteoarthritis[1]. The study aims to:

  • Evaluate the effectiveness and tolerance of NSAIDs in improving walking ability for osteoarthritis patients[1].
  • Assess patient compliance with the program and identify factors that contribute to its success[1].
  • Investigate the impact of central sensitization (a condition where the nervous system becomes overly sensitive to pain) on the effectiveness of NSAID treatment[1].

This research may provide valuable insights into the optimal use of Niflumic Acid and other NSAIDs in the management of osteoarthritis, particularly in conjunction with exercise programs.

Aspect Details
Study Title Patient Walking Rehabilitation Program with osteoarthritis of the hip or knee helped by a one-off anti-inflammatory treatment (PERIPATEI)
Main Objective Study the efficacy and tolerance of NSAID intake in a walking rehabilitation program for hip or knee osteoarthritis patients
Participant Age Range 50 to 70 years old
Key Inclusion Criteria Idiopathic osteoarthritis of hip or knee, walking pain rated at least 4/10, limited walking ability
Main Exclusion Criteria Pregnancy, certain medical conditions, hypersensitivity to NSAIDs, severe organ dysfunction
Primary Endpoint 30% increase in monthly target movements without NSAID discontinuation due to intolerance
Drug Studied Niflumic Acid (NIFLURIL 250 mg, capsule)
Maximum Daily Dose 500 mg
Administration Route Oral

FAQ

  • What is the main goal of this clinical trial? The main goal is to study the effectiveness and tolerance of using a non-steroidal anti-inflammatory drug (NSAID), specifically Niflumic Acid, as part of a walking rehabilitation program for patients with hip or knee osteoarthritis.
  • Who can participate in this clinical trial? Participants should be men or women aged 50 to 70 with confirmed idiopathic osteoarthritis of the hip or knee, experiencing significant walking pain and limited mobility. They must also meet other specific inclusion criteria and not have any of the listed exclusion conditions.
  • What is Niflumic Acid and how is it used in this trial? Niflumic Acid is a non-steroidal anti-inflammatory drug (NSAID) used to reduce pain and inflammation. In this trial, it is being studied as part of a walking rehabilitation program to help patients with osteoarthritis improve their mobility.
  • What are the potential benefits of participating in this trial? Participants may experience improved walking ability and reduced pain associated with their osteoarthritis. The trial aims to increase the monthly number of target movements by at least 30% compared to the baseline observation period.
  • Are there any risks or side effects associated with Niflumic Acid? As with all NSAIDs, Niflumic Acid may have side effects. The trial excludes individuals with certain medical conditions or a history of adverse reactions to NSAIDs to minimize risks. Participants will be closely monitored throughout the study for any potential side effects or complications.

Ongoing Clinical Trials on Niflumic Acid

  • Study on Walking Rehabilitation for Hip or Knee Osteoarthritis Using Ketoprofen and Drug Combination for Patients with Osteoarthritis

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • Osteoarthritis: A type of joint disease that results from breakdown of joint cartilage and underlying bone, causing pain, stiffness, and reduced mobility.
  • Non-steroidal anti-inflammatory drug (NSAID): A class of medications that reduces pain, fever, and inflammation. Niflumic Acid is an example of an NSAID.
  • Idiopathic: A term used in medicine to describe a condition that arises spontaneously or for which the cause is unknown.
  • Walking rehabilitation program: A structured exercise plan designed to improve walking ability and mobility in patients with conditions that affect movement, such as osteoarthritis.
  • Kellgren and Lawrence stage: A system used to classify the severity of knee osteoarthritis using five grades, from 0 (no radiographic features of osteoarthritis) to 4 (severe osteoarthritis).
  • Temporal summation: A pain assessment method that measures how the nervous system processes repeated painful stimuli, which can indicate central sensitization in chronic pain conditions.
  • Visco-supplementation: A medical procedure for osteoarthritis in which a gel-like fluid is injected into a joint to supplement the natural synovial fluid and act as a lubricant and shock absorber.
  • Creatinine clearance: A test that measures how well your kidneys are working, specifically how much blood the kidneys can filter in a minute.

References

  1. http://clinicaltrials.eu/trial/study-on-walking-rehabilitation-for-hip-or-knee-osteoarthritis-using-ketoprofen-and-drug-combination-for-patients-with-osteoarthritis/